Nature spoke with Emily Hickey, Corporate Senior VP of Global Discovery, about our mission to deliver quality science to our partners while making the drug discovery ecosystem easier to navigate.
Charles River is pleased to announce the expansion of our GMP cell banking and viral manufacturing facilities to accommodate growing client needs.
Neuroscience 2015 offered our experts the opportunity to collaborate with top scientists from across the globe as we work to advance research in this rapidly transforming field. During this year’s meeting, our team of leading Central Nervous System (CNS) researchers presented, either independently or in conjunction with our clients, 25 posters to showcase our latest research findings.
Combining our Endosafe® and Accugenix® brands with the strategic acquisition of Celsis® makes us the industry’s only comprehensive provider of micro QC products and services.
Flow cytometry has become an indispensable tool as scientists explore ways of enabling native immune responses to inhibit tumor growth.
In addition to visits from our clients’ auditors, we are regularly inspected by all major regulatory authorities. So far in 2015, we have been audited by several global regulatory authorities, including the FDA and AAALAC.
We now offer an imiquimod-induced psoriasis mouse model, which includes in-life clinical and histopathological evaluation of skin, as well as cytokine analysis.
We are pleased to offer cell line identification through a DNA profiling method known as barcode analysis.
The 360 Diagnostics™ R&D team recently completed the validation of new PCR assays for infectious diseases that commonly affect zebrafish colonies.
Charles River now has the ability to monitor animal behavior in home cages for periods of up to 9 months.